Literature DB >> 33633675

Case Report: Neuropsychological Findings in IgLON5 Antibody Disorder.

Jasmin El Shazly1,2, Martin Juenemann1,3, Tibo Gerriets1,3,4, Marlene Tschernatsch3,4.   

Abstract

IgLON5 antibody encephalopathy is a rare but increasingly recognized disorder with a variety of clinical signs. Typical symptoms are sleep disorder, gait disturbances, signs of bulbar dysfunction and a variety of neurological symptoms like oculomotor abnormalities and movement disorders. In addition, cognitive decline can be a prominent symptom. So far, there are only a few studies that have dealt with the course and possible treatment options of IgLON5 antibody encephalopathy. In this study the clinical case of a female patient with IgLON5 antibody disease and the response to treatment is described. Here we report on the case of a 67-year-old female patient who showed cognitive deterioration, gait difficulties, and chronic obstructive sleep disorder. The diagnostic course showed a positive anti-IgLON5 serum and anti-IgLON5 IgG antibodies in cerebrospinal fluid. The patient was subsequently treated with high dosage i.v. methylprednisolone, i.v. immunoglobulins and plasmapheresis. Neuropsychological tests showed cognitive deficits in different domains, including verbal and visual memory. Both, neuropsychological deficits and antibody titer, showed an improvement after plasmapheresis. The presented case shows that IgLON5 disease can present with rapidly progressing cognitive deterioration as the prominent symptom, adding to the variety of clinical signs in this disorder. Testing for IgLON5-antibodies should be considered in patients with progressing cognitive decline, especially if accompanied by sleep disorders or neurological symptoms like oculomotor abnormalities, dysautonomia or bulbar signs.
Copyright © 2021 El Shazly, Juenemann, Gerriets and Tschernatsch.

Entities:  

Keywords:  IgLON5; autoimmune encephalopathy; cognitive deficits; neuropsychological findings; sleep disorder

Year:  2021        PMID: 33633675      PMCID: PMC7901917          DOI: 10.3389/fneur.2021.632497

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  15 in total

1.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; R C Mohs; H Rogers; G Fillenbaum; A Heyman
Journal:  Psychopharmacol Bull       Date:  1988

2.  Hypothalamic-Bulbar MRI Hyperintensity in Anti-IgLON5 Disease with Serum-Restricted Antibodies: A Case Report and Systematic Review of Literature.

Authors:  Matteo Tagliapietra; Emma Frasson; Davide Cardellini; Sara Mariotto; Sergio Ferrari; Gianluigi Zanusso; Mauro Plebani; Salvatore Monaco
Journal:  J Alzheimers Dis       Date:  2020-12-16       Impact factor: 4.472

3.  Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopathy.

Authors:  Annachiara Cagnin; Sara Mariotto; Michele Fiorini; Marina Gaule; Nicola Bonetto; Matteo Tagliapietra; Emanuele Buratti; Gianluigi Zanusso; Sergio Ferrari; Salvatore Monaco
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Clinical manifestations of the anti-IgLON5 disease.

Authors:  Carles Gaig; Francesc Graus; Yarko Compta; Birgit Högl; Luis Bataller; Norbert Brüggemann; Caroline Giordana; Anna Heidbreder; Katya Kotschet; Jan Lewerenz; Stefan Macher; Maria J Martí; Teresa Montojo; Jesus Pérez-Pérez; Inmaculada Puertas; Caspar Seitz; Mateus Simabukuro; Nieves Téllez; Klaus-Peter Wandinger; Alex Iranzo; Guadalupe Ercilla; Lidia Sabater; Joan Santamaría; Josep Dalmau
Journal:  Neurology       Date:  2017-04-05       Impact factor: 9.910

5.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

6.  A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study.

Authors:  Lidia Sabater; Carles Gaig; Ellen Gelpi; Luis Bataller; Jan Lewerenz; Estefanía Torres-Vega; Angeles Contreras; Bruno Giometto; Yaroslau Compta; Cristina Embid; Isabel Vilaseca; Alex Iranzo; Joan Santamaría; Josep Dalmau; Francesc Graus
Journal:  Lancet Neurol       Date:  2014-04-03       Impact factor: 44.182

7.  IgLON5 disease responsive to immunotherapy.

Authors:  Michael Bonello; Anu Jacob; Mark A Ellul; Erandi Barker; Robert Parker; Samantha Jefferson; Sundus Alusi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-08-07

8.  Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis.

Authors:  Niels Hansen; Sina Hirschel; Winfried Stöcker; Anja Manig; Hannah Sönne Falk; Marielle Ernst; Ruth Vukovich; Inga Zerr; Jens Wiltfang; Claudia Bartels
Journal:  Front Psychiatry       Date:  2020-07-03       Impact factor: 4.157

9.  IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.

Authors:  Josephe A Honorat; Lars Komorowski; Keith A Josephs; Kai Fechner; Erik K St Louis; Shannon R Hinson; Sabine Lederer; Neeraj Kumar; Avi Gadoth; Vanda A Lennon; Sean J Pittock; Andrew McKeon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-07-18

10.  IgLON5-Associated Encephalitis With Atypical Brain Magnetic Resonance Imaging and Cerebrospinal Fluid Changes.

Authors:  Massimiliano Montagna; Rizvana Amir; Ilse De Volder; Martin Lammens; Jef Huyskens; Barbara Willekens
Journal:  Front Neurol       Date:  2018-05-17       Impact factor: 4.003

View more
  1 in total

Review 1.  Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives.

Authors:  Natalia Madetko; Weronika Marzec; Agata Kowalska; Dominika Przewodowska; Piotr Alster; Dariusz Koziorowski
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.